Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

BioCardia Inc (BCDA) USD0.001

Sell:$2.77 Buy:$3.20 Change: $0.05 (1.67%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$2.77
Buy:$3.20
Change: $0.05 (1.67%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
Sell:$2.77
Buy:$3.20
Change: $0.05 (1.67%)
Market closed |  Prices as at close on 21 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioCardia, Inc. is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication.

Contact details

Address:
125 Shoreway Rd Ste B
SAN CARLOS
94070-2718
United States
Telephone:
+1 (650) 2260120
Website:
www.biocardia.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCDA
ISIN:
US09060U5074
Market cap:
$52.47 million
Shares in issue:
16.87 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Peter Altman
    President, Chief Executive Officer, Director
  • David McClung
    Chief Financial Officer
  • Edward Gillis
    Senior Vice President - Devices
  • Sujith Shetty
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.